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Abstract
Newborns are at relatively high risk for developing hypoglycaemia in the first 24 h after birth. Well-known risk factors are
prematurity, small for gestational age (SGA) or large for gestational age (LGA), and maternal pre-existent or gestational diabetes
mellitus. Prolonged hypoglycaemia is associated with poor neurodevelopmental outcomes; hence, prevention through proper
monitoring and treatment is important. Given the ongoing debate concerning frequency and duration of screening for neonatal
hypoglycaemia, therefore, we investigated the frequency and duration of glucose monitoring safe to discover neonatal
hypoglycaemia in different risk groups. Data of newborns at risk for hypoglycaemia were retrospectively collected and analysed.
Blood glucose concentrations were measured 1, 3, 6, 12, and 24 h after birth. Moderate hypoglycaemia was defined as a blood
glucose concentration of < 2.2 mM and severe hypoglycaemia as a concentration of < 1.5 mM. Of 1570 newborns, 762 (48.5%)
had at least one episode of hypoglycaemia in the first 24 h after birth; 30.6% of them had severe hypoglycaemia (all in the first 9 h
after birth). Only three SGA and two LGA newborns had a first moderate asymptomatic hypoglycaemic episode beyond 12 h
after birth. The incidence of hypoglycaemia increased with accumulation of multiple risk factors.
Conclusion: Safety of limiting the monitoring to 12 h still has to be carefully evaluated in the presence of SGA or LGA
newborns; however, our results suggest that 12 h is enough for late preterm newborns (> 34 weeks) and maternal diabetes.
What is Known:
•Newborns are at relatively high risk for developing hypoglycaemia and such hypoglycaemia is associated with adverse neurodevelopmental outcomes.
• Proper glucose monitoring and prompt treatment in case of neonatal hypoglycaemia are necessary.
What is New:
• Glucose monitoring 12 h after birth is proficient for most newborns at risk.
• Maternal diabetes leads to the highest risk of early neonatal hypoglycaemia and newborns with more than one risk factor are at increased risk of
hypoglycaemia.
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Abbreviations
CGM Continuous glucose monitoring
DM Diabetes mellitus
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GDM Gestational diabetes mellitus
LGA Large for gestational age
mM Millimolar (1 mmol/litre)
POC Point-of-care
SD Standard deviation
SGA Large for gestational age
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Introduction
To date, there is still little evidence and consensus regard-
ing definition, indication, and frequency of screening for
neonatal hypoglycaemia, one of the most frequently en-
countered problems in neonatology. Newborns are at rel-
atively high risk for developing hypoglycaemia in the first
24 h after birth [10]. The incidence of hypoglycaemia in
apparently healthy newborns varies widely (between 4
and 40%) depending amongst others on definition of
hypoglycaemia, timing of glucose monitoring after deliv-
ery, and population studied [16, 21].
Risk factors for neonatal hypoglycaemia are prematurity
(< 37 weeks of gestation), being small for gestational age
(SGA) (birth weight ≤ 10th percentile for GA), large for ges-
tational age (LGA) (birth weight ≥ 90th percentile for GA),
and pre-existent maternal diabetes (diabetes mellitus type 1,
type 2 (T1DM, T2DM)) or gestational diabetes mellitus
(GDM) [2, 3, 11, 26].
In apparently healthy infants, glucose concentrations tend
to decrease after birth, reach a nadir 1 h after birth, increase
again, and stabilise after one day [2, 16]. The majority of first
hypoglycaemic episodes occur in the first 24 h after birth
(81%), from which 48% within 6 h [12].
Recurrent severe hypoglycaemia is associated with poor
neurodevelopmental outcomes; however, duration and se-
verity of hypoglycaemia to cause injury are unknown.
The management of the asymptomatic infant at risk for
low glucose remains controversial. Despite this, preven-
tion of (prolonged) hypoglycaemia by screening and
treatment seems rational [3, 13, 19].
Existing guidelines for screening and treatment recom-
mend glucose monitoring in newborns at risk but vary in
(1) definition of hypoglycaemia (between 2.2 and
2.6 mM), (2) total monitoring time (12–48 h after birth),
and (3) time intervals (between 1 and 8 h). This is illus-
trating the lack of consensus regarding the frequency and
duration of glucose monitoring deemed necessary and
safe to discover neonatal hypoglycaemia [2, 7, 12, 15,
18]. Furthermore, different risk factors may prompt a dif-
ferent strategy. Therefore, we studied the onset of the first
hypoglycaemic episode in newborns at risk according to
their risk factors.
Materials and methods
This is a retrospective observational cohort study. We enrolled
all eligible newborns born and admitted at Radboudumc
Amalia Children’s Hospital Nijmegen, the Netherlands, from
a four-year period (2010–2013). Inclusion criteria were gesta-
tional age (GA) ≥ 34 weeks and screening indication accord-
ing to our local guideline: prematurity (< 37 weeks of gesta-
tion), SGA, LGA, and maternal diabetes of any kind (identical
to recommendations by the American Academy of Pediatrics
(AAP)) [3, 4]. Exclusion criteria were severe asphyxia (Apgar
5 min after birth ≤ 3) [1] and death within the first 24 h after
birth. In the first 24 h after birth, moderate hypoglycaemia and
severe hypoglycaemia were defined as a blood glucose con-
centration (GC) between 1.5–2.1 mM and below 1.5 mM,
respectively, moderate and severe reflecting therapy in this
case. Blood glucose concentrations were measured on capil-
lary blood samples taken by several point-of-care (POC) glu-
cose meters during this period (HemoCue Glu201DM, Nova
StatStrip GluCard memory PC, Roche OMNI-56 blood gas
analyser and Siemens Rapid lab 1265). In case of
hypoglycaemia (GC < 2.2 mM), capillary blood was sent to
the laboratory for confirmation.
Blood glucose samples were taken 1, 3, 6, 12, and 24 h
after birth according to local guidelines [9]. In case of any
clinical signs of hypoglycaemia, such as twitching and drows-
iness, additional glucose samples were taken.
Feeding was initiated in the first hour after birth.
Breastfeeding was encouraged throughout pregnancy, but
the ultimate choice between breastfeeding and formula feed-
ing was made by the parents. In our hospital (as in the
Netherlands), approximately 80% of women start with exclu-
sive breastfeeding post-delivery [22]. Feeding is continued at
least every 3 h, with breastfeeding sometimes more often.
Newborns with moderate hypoglycaemia were treated with
increased enteral carbohydrate intake, either through more
frequent breast feedings or (additional) formula feeding. In
case of repeated moderate hypoglycaemia (≥ 3×), continuous
intravenous glucose 10% was started after administration of
2 ml/kg bolus. Newborns with severe hypoglycaemia were
immediately treated with continuous intravenous glucose
10% and a bolus.
Birth percentiles, SGA (< 10th percentile) or LGA (> 90th
percentile), were calculated using Dutch birth weight curves
(https://www.perined.nl/producten/geboortegewichtcurven).
Relevant maternal and neonatal information and GC were
extracted from patient files. Our primary outcome was time of
first hypoglycaemia, which we studied in all risk factors sep-
arately. When hypoglycaemia was described in discharge cor-
respondence but data on timing of blood glucose concentra-
tions were missing of more than two standardised sample
moments, cases were only used for overall analysis.
For statistical analysis, SPSS software version 20was used.
Normally, distributed data were expressed as percentage and
mean (SD). Median (range) was used for skewed distributed
data. For 2 × 2 tables, chi-square test was performed.
Multivariate logistic regression analyses were used to examine
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the association between (severe) hypoglycaemia and possible
risk factors, including screening indications, background in-
formation, and other complications. A p value < 0.05 was
considered statistically significant.
This study was exempt from Regional Ethics Review
Board approval, under the legal requirements for clinical re-
search in the Netherlands.
Results
We enrolled 1628 newborns with risk factors for
hypoglycaemia of which 1573 met our inclusion and exclu-
sion criteria. Data of three newborns were unavailable. The
final analysis was performed on data from 1570 newborns. In
327 cases, data of more than two sample moments were miss-
ing. These cases were only used for the overall analysis
(hypoglycaemia 125/327). Newborns at risk were premature
(33.5%), SGA (32.4%), LGA (27.6%), or born to a diabetic
mother (19.1%) (Table 1). Most newborns had one risk factor
(87.1%), 12.1% two risk factors, and 0.7% three risk factors
(Fig. 1). In the first hour after birth, GCs for this cohort reach
their lowest values. After that, blood GCs remain stable at a
value of 3.1–3.4 mM (Fig. 2).
Of 1570 patients at risk, 762 (48.5%) suffered from at least
one episode of hypoglycaemia. One-third of hypoglycaemic
episodes were severe (< 1.5 mM), with maternal pre-existing
diabetes as the main risk factor (54.5%) (Table 1). The prev-
alence of hypoglycaemia is similar in different birth weight
groups (p > 0.05) (Table 1). Pre-existent maternal diabetes led
to early hypoglycaemia (first hour after birth) in 21 cases
(75%) (Table 2).
In GDM, the majority of newborns (100/113; 88.5%) had a
hypoglycaemia within 3 h after birth. Hypoglycaemia occur-
ring more than 12 h after birth for the first time was seen in
only five newborns (Table 2). One SGA newborn had a GC of
2.1 mM 15 h after birth, and three LGA newborns and one
SGA newborn had moderate hypoglycaemias (GC 1.7, 1.9,
Table 1 Maternal, gestational, and newborn characteristics
Overall Glucose < 2.2 mM ‘hypoglycaemia’ Glucose < 1.5 mM
‘severe hypoglycaemia’
Total number of newborns 1570 762/1570 (48.5%) 271/1570 (17.2%)
Gestational age, weeks* 38.29 (36.43–39.86) 37.86 (36.29–39.43) 37.49 (36.14–38.86)
Birth weight, g** 3106 ± 814 3043 ± 819 2980 ± 783
Sex
Male 804/1570 (51.2%) 395/804 (49.1%) 133/804 (16.5%)
Females 766/1570 (48.8%) 367/766 (47.9%) 138/766 (18.0%)
Single/multiple birth
Singleton 1385/1570 (88%) 657/1385 (47.4%) 238/1385 (17.2%)
Twin 164/1570 (10.4%) 72/165 (43.9%) 27/165 (16.4%)
Triplet 20/1570 (1.3%) 8/20 (40.0%) 6/20 (30.0%)
Preterm delivery
Total preterm deliveries 526/1570 (33.5%) 298/526 (56.7%) 115/526 (21.9%)
34–35 weeks 102/526 (19.4%) 51/102 (50.0%) 22/102 (21.6%)
35–36 weeks 163/526 (31.0%) 85/163 (52.1%) 36/163 (22.1%)
36–37 weeks 261/526 (49.6%) 162/261 (62.1%) 57/261 (21.8%)
Weight
LGA (p > 90) 433/1570 (27.6%) 198/433 (45.7%) 61/433 (14.1%)
Extremely LGA (p > 97.7) 114/1570 (7.4%) 52/114 (45.6%) 17/114 (14.9%)
SGA (p < 10) 508/1570 (32.4%) 233/508 (45.9%) 115/508 (22.6%)
Extremely SGA (p < 2.3) 131/1570 (8.3%) 69/131 (52.7%) 22/131 (16.8%)
Diabetes
Total 300/1570 (19.1%) 154/300 (51.3%) 66/300 (22.0%)
T1DM/ T2DM 41/300 (13.7%) 33/41 (80.5%) 18/41 (43.9%)
GDM 259/300 (86.3%) 121/259 (46.7%) 48/259 (18.5%)
Data are number (percentage). Percentages are of total number of newborns or of individual and overall numbers of newborns in the different groups
*Median (25th–75th percentile)
**Mean (SD)
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2.1, and 2.1 mM respectively) 24 h after birth. These new-
borns were all treated with additional feedings only.
In the group with other complications, e.g. congenital
abnormalities, respiratory distress, or (risk for) infection,
significantly less newborns developed a hypoglycaemic
episode (p = 0.04).
The overall prevalence of hypoglycaemia increased with
increasing number of risk factors (one risk factor (43–55%),
comparing to the group with two risk factors (51–84%, p =
0.011) and the group with three risk factors (50–89%, p =
0.004)) (Fig. 1).
Multivariate logistic regression analysis including all po-
tential risk factors, sex, single/multiple birth, and other com-
plications (congenital abnormalities, respiratory distress and
(risk for) infection) showed that hypoglycaemia was signifi-
cant associated with prematurity (OR = 1.545, 95% CI 1.00–
Numerator = number of newborns with hypoglycaemia in different risk group(s)                                  
Denominator = total number of newborns of different risk group(s)
Percentage = number of newborns with hypoglycaemia of the total numbers of newborns in the specifically risk group
Preterm
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Fig. 2 Median blood glucose concentration of total newborns (median, 25th and 75th percentile)
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2.02, p < 0.05), pre-existent DM (T1DM and T2DM com-
bined) (OR = 4.23, 95% CI 1.81–10.32, p = 0.001), and other
complications (OR = 0.70, 95% CI 0.53–0.94, p = 0.018).
Also, in case of severe hypoglycaemia, significant association
was found with newborns born to mothers with pre-existent
DM (OR = 4.74, 95% CI 2.44–9.20, p < 0.001) and prematu-
rity (OR = 1.84, 95% CI 1.24–2.73, p = 0.002).
Discussion
The overall incidence of hypoglycaemia in our cohort of ne-
onates at risk was 48.5%. For most newborns at risk, it is safe
to stop monitoring GCs 12 h after birth. The highest incidence
of hypoglycaemia was related to maternal diabetes and
there is an increasing risk of hypoglycaemia with in-
creasing number of risk factors. The majority of first
hypoglycaemias occurred within 3 h after birth, compa-
rable to other studies [14, 16].
The overall incidence of hypoglycaemia in our cohort is
rather high; other studies report 6.8–51% [6, 12, 20, 23]. This
might be due to our selection criteria for newborns at risk for
hypoglycaemia although our screening indications are identi-
cal to those recommended by the AAP [3]. Other possible
explanations are our standardised and frequent monitoring
and difference in GC cut-off point to define hypoglycaemia.
Hypoglycaemia was defined as a GC< 2.6mMbyHarris et al.
[12] (overall incidence 51%) and a GC < 1.6 mMby Schaefer-
Graf et al. [23] (overall incidence 25.2%); by means of this,
incidence of hypoglycaemia might be influenced. Our lowest
level of action is 2.2 mM in the first 24 h which is comparable
to the actionable range recommended by the AAP (4–24 h
after birth, 1.9–2.5 mM) [3].
A wide range of policies regarding duration of glucose
concentration monitoring exists [2, 7, 12, 15]. Some authors
state that the same screening strategy should be applied to
each risk group while others suggest to differentiate between
risk groups [12]. Different studies suggest that LGA newborns
and newborns of diabetic mothers should have their monitor-
ing discontinued 12 h after birth (if GC is ≥ 2.6 mM) [2, 7] and
SGA newborns and late preterm newborns after 24 h [2], 36 h
[7], or 48 h [15].
The high incidence of hypoglycaemia in offspring of
mothers with pre-existent DM (81%) was comparable to the
incidence seen in the study ofMaayanMetzger et al. (54%GC
< 2.6 mM and 83% GC < 2.2 mM) [18] but rather high com-
pared to the study of Harris et al. (49%) [12]. However, in the
latter study, no distinction between maternal pre-existent DM
and GDM was defined.
More than one risk factor resulted in higher incidence (Fig.
2) which is in contrast to the study of Harris et al. in which no
significant difference was found [12]. This might be due to the
relative small sample size in their study.
The nadir 1–2 h after birth in blood GC is also observed in
apparently health newborns and is considered part of normal
adaptation to postnatal life by several authors, although it is
not consistently described [2, 14, 16].
Our data illustrate that 96.7% (710/734) of all newborns
who developed hypoglycaemia had the first hypoglycaemia
within 6 h after birth. Since there were only five cases of mild
asymptomatic hypoglycaemia beyond 12 h, all treated with
additional feeding only, one could argue to stop glucose mon-
itoring after 12 h for all risk groups. Safety of limiting the
monitoring to 12 h still has to be carefully evaluated in the
presence of SGA or LGA newborns.
Some limitations of this study should be addressed. Due to
the retrospective design, it was not possible to obtain the exact
glucose concentrations in 327 cases. Since the introduction of
the electronic patient files, values of blood glucose concentra-
tions are directly stored in these files. Furthermore, not all
samples were obtained at the exact prescribed time points,
which was mainly due to breastfeeding on demand and sam-
pling just prior to intake (recommended clinical practice).
Also, in this time period, several blood glucose meters and
Table 2 Timing of first hypoglycaemia according to screening indication
Timing of first hypoglycaemia All newborns T1DM, T2DM GDM Preterm SGA LGA
N = 1570* N = 41 N = 259 N = 526 N = 508 N = 433
0–1 h after birth 512/1428 21/34 83/237 207/457 135/454 134/386
> 1–2 h after birth 19/60 0/2 5/11 8/27 3/16 6/16
> 2–3 h after birth 102/888 5/13 12/149 33/238 45/317 16/240
> 3–5 h after birth 3/22 0/0 1/5 1/7 0/6 1/6
> 5–9 h after birth 71/797 1/9 8/136 14/210 32/279 24/224
> 9–12 h after birth 19/768 1/8 4/135 7/206 3/257 4/218
> 12–15 h after birth 1/33 0/0 0/4 0/11 0/11 1/10
> 15–18 h after birth 0/65 0/1 0/9 0/26 0/17 0/17
> 18–24 h after birth 4/667 0/7 0/119 0/177 3/223 1/191
*There are newborns with more than one risk factor
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analysers were used. It is known that results of POC glucose
meters in the critical range may be unreliable [24]. To mini-
mise misdiagnosis, blood samples, which showed a GC below
2.2 mM, were retested in the clinical laboratory. Moreover,
variance in reliability of POC glucose meters is depending
on variability in instrument analytical performance [17] and
interaction between users and POC glucose meters [8].
Continuous glucose monitoring (CGM) has been studied in
neonates and results are promising. CGM could potentially
decrease number of blood samples and the exposure to
hypoglycaemia. Furthermore, it is feasible, calibration can
be as low as 12 hourly, and it has limited side effects even in
premature newborns (birth weight < 1500 g) and is well tol-
erated [5]. However, no association with improved clinical
outcomes has been confirmed yet. There are technical issues
to be improved as well, for example the provided range of 2.2
to 22.0 mM, which is insufficient to detect neonatal
hypoglycaemia [25]. Randomised trials should demonstrate
long-term outcome data using CGM [5, 25]. In our centre, ~
85% is Caucasian; therefore, our results may need to be con-
firmed in other ethnic populations.
To our knowledge, this is the largest published study
that specifically investigated the length of time that is
necessary in neonatal glucose monitoring. The newborns
were selected based on strict inclusion criteria for each
separate risk factor and GC were measured using a
standardised protocol.
In conclusion, the onset of first hypoglycaemia did not
occur beyond 12 h of glucose monitoring after birth in prema-
turity and maternal diabetes in the observed time frame.
Multiple risk factors and an inappropriate birth weight for
gestational age may increase the risk of hypoglycaemic
episode.
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